Post-Award Reporting Sample Clauses

Post-Award Reporting. The Duke CTSI tracks significant events (“translational units”) required to translate a scientific discovery from laboratory, clinical or population studies into clinical or population-based applications to improve health by reducing disease incidence, morbidity and mortality. The Duke CTSI will contact investigators annually to determine if any translational units have been achieved as a result of this award. Examples include:  Abstracts/presentations, manuscripts, published guidelines  Follow-on funding (e.g., grants, SBIR/STTR, angel and venture capital investment)  Milestones achieved in animal models, manufacturing and toxicity campaigns  Regulatory meetings and filings (e.g., 510K, IDE, IND, BLA, NDA)  Initiation of appropriate clinical studies  Improved diagnosis or treatment of disease  Implementation in clinical practice or community  Translation of models to other geographical areas  Translation of models to other therapeutic areas  Clinical outcomes in practice and communities  Clinical guideline or guidelines updated  Agreements with partners and strategic collaborators to translate more broadly  Commercialization (e.g. new intellectual property, patent applications, license, commercial partnerships, start-up company)  Direct-to-consumer interactions (e.g. apps)  When requested, all awardees will be expected to provide updates of publications and other translational units that originated from the award. Awardees that leave the institution within 5-years post award period will be expected to provide updated contact information for future communications. Awardees and applicants will be asked to serve as reviewers for future Duke CTSI funding opportunities.
Sample 1Sample 2See All (6)
AutoNDA by SimpleDocs
Post-Award Reporting. The Duke CTSI tracks significant events (“translational units”) required to translate a scientific discovery from laboratory, clinical or population studies into clinical or population-based applications to improve health by reducing disease incidence, morbidity and mortality. The Duke CTSI will contact investigators annually to determine if any translational units have been achieved as a result of this award. Examples include:  Abstracts/presentations, manuscripts, published guidelines  Follow-on funding (e.g., grants, SBIR/STTR, angel and venture capital investment)  Milestones achieved in animal models, manufacturing and toxicity campaigns  Regulatory meetings and filings (e.g., 510K, IDE, IND, BLA, NDA)  Initiation of appropriate clinical studies  Improved diagnosis or treatment of disease  Implementation in clinical practice and community  Translation of models to other geographical areas  Translation of models to other therapeutic areas  Clinical outcomes in practice and communities  Agreements with partners and strategic collaborators to translate more broadly  Commercialization (e.g. new intellectual property, patent applications, license, commercial partnerships, start-up company)  Direct-to-consumer interactions (e.g. apps) When requested, all awardees will be expected to provide updates of publications and other translational units that originated from the award. Awardees and applicants are expected to serve as reviewers for future Duke CTSI funding opportunities. CONTACT INFORMATION
Sample 1
Post-Award Reporting. The DTRI tracks significant events (“translational units”) required to translate a scientific discovery from laboratory, clinical or population studies into clinical or population-based applications to improve health by reducing disease incidence, morbidity and mortality. The DTRI will contact investigators annually to determine if any translational units have been achieved as a result of this award. Examples include:  Abstracts/presentations, manuscripts, published guidelines  Follow-on funding (e.g., grants, SBIR/STTR, angel investment)  Milestones achieved in animal models, manufacturing and toxicity campaigns  Regulatory meetings and filings (e.g., 510K, IDE, IND, BLA, NDA)  Initiation of appropriate clinical studies  Improved diagnosis or treatment of disease  Implementation in clinical practice and community  Commercialization (e.g. new intellectual property, patent applications, license, commercial partnerships, start-up company)  Direct-to-consumer interactions (e.g. mobile health apps) When requested, all awardees will be expected to provide updates of publications and other translational units that originated from the award. All publications that are the direct result of this funding must reference: “Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Publications must also be registered in PubMed Central. Awardees are expected to serve as reviewers for future DTRI funding opportunities. MORE INFORMATION
Sample 1
Post-Award Reporting. On or before December 1, 2020, Recipient shall provide KEDC verification, in a form and substance reasonably acceptable to KEDC, that Recipient used Award funds for the Approved Use of Award Funds. KEDC may require that Recipient submit copies of receipts, canceled checks, account statements, or other similar documentation showing that Recipient used the Award funds for the Approved Use of Award Funds.
Sample 1

Related to Post-Award Reporting

  • PERFORMANCE MONITORING AND REPORTING Performance indicators

  • Quarterly Contractor Performance Reporting Customers shall complete a Contractor Performance Survey (Exhibit I) for each Contractor on a Quarterly basis. Customers will electronically submit the completed Contractor Performance Survey(s) to the Department Contract Manager no later than the due date indicated in Contract Exhibit D, Section 17, Additional Special Contract Conditions. The completed Contractor Performance Survey(s) will be used by the Department as a performance-reporting tool to measure the performance of Contractors. The Department reserves the right to modify the Contractor Performance Survey document and introduce additional performance-reporting tools as they are developed, including online tools (e.g. tools within MyFloridaMarketPlace or on the Department's website).

  • Ongoing Performance Measures The Department intends to use performance-reporting tools in order to measure the performance of Contractor(s). These tools will include the Contractor Performance Survey (Exhibit H), to be completed by Customers on a quarterly basis. Such measures will allow the Department to better track Vendor performance through the term of the Contract(s) and ensure that Contractor(s) consistently provide quality services to the State and its Customers. The Department reserves the right to modify the Contractor Performance Survey document and introduce additional performance-reporting tools as they are developed, including online tools (e.g. tools within MFMP or on the Department's website).

  • Performance Reporting The State of California is required to submit the following financial reports to FEMA:

  • Post-Award Small Business Program Re Representation If applicable, The Contractor shall report timely and accurately their small business program re-representation and update XXX.xxx.

  • Registry Performance Specifications Registry Performance Specifications for operation of the TLD will be as set forth in Specification 10 attached hereto (“Specification 10”). Registry Operator shall comply with such Performance Specifications and, for a period of at least one (1) year, shall keep technical and operational records sufficient to evidence compliance with such specifications for each calendar year during the Term.

  • Long-Term Incentive Awards The Executive shall participate in any long-term incentive awards offered to senior executives of the Company, as determined by the Compensation Committee.

  • Long-Term Incentive Award During the Term, Executive shall be eligible to participate in the Company’s long-term incentive plan, on terms and conditions as determined by the Committee in its sole discretion taking into account Company and individual performance objectives.

  • Annual Performance Bonus In each calendar year of the Term of Employment, Executive shall be eligible to receive an annual incentive bonus (the “Annual Bonus”) payable in cash, pursuant to the performance criteria and targets established and administered by the Board (or a committee of directors to whom such responsibility has been delegated by the Board), with a target Annual Bonus of at least 100% of his Base Salary. The Annual Bonus payable to Executive each year shall be determined and payable as soon as practicable after year-end for such year (but no later than March 15th). The Executive’s cash bonus for the stub period of 2017 will be determined in the reasonable business judgment of the Board or another committee of directors to whom such responsibility has been delegated by the Board. To be entitled to receive any Annual Bonus, except as otherwise provided in Sections 5(c) and 5(d), Executive must remain employed through the last day of the calendar year to which the Annual Bonus relates.

  • Performance Measure The specific representation of a process or outcome that is relevant to the assessment of performance; it is quantifiable and can be documented

Time is Money Join Law Insider Premium to draft better contracts faster.